Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 6, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding increases in their personal holdings of Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Share Price: GBP 14.440 per Ordinary Share.
- Transaction Type: Re-investment of dividends paid on October 5, 2006.
Material Changes
The filing details specific increases in shareholdings for the following individuals following the dividend re-investment:
- Mr J S Heslop: 145 shares
- Mrs P A Heslop: 55 shares
- Mr R Bondy: 232 shares
- Mr D Learmouth: 30 shares
- Dr D Pulman: 126 shares
- Mrs C Pulman: 13 shares
- Mr A Witty: 20 shares
- Mrs C Witty: 251 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification compliant with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of shares acquired by directors and connected persons via dividend re-investment on October 5, 2006.
- Confirm the share price of GBP 14.440 used for the transaction.
- Note that this filing contains no operational or financial performance data for the period.